Wegovy Side Effects: Incidence Rates Across Clinical Trials

How Common Are Wegovy Side Effects? The STEP Trial Overview

The four STEP (Semaglutide Treatment Effect in People with Obesity) trials form the core evidence base for Wegovy's safety profile. Across these trials, gastrointestinal events dominated the adverse-event tables, appeared early in the dose-escalation phase, and resolved for most participants within 4 to 8 weeks of reaching a stable dose. Serious adverse events were uncommon but not rare.

STEP 1: The Foundational Safety Dataset

STEP 1 enrolled 1,961 adults with a BMI of 30 or higher (or 27 with at least one weight-related comorbidity) and no diabetes. Participants received semaglutide 2.4 mg or placebo for 68 weeks [1]. The incidence figures below come directly from the published New England Journal of Medicine report.

Gastrointestinal adverse events by incidence in the semaglutide arm versus placebo:

| Adverse Event | Semaglutide 2.4 mg | Placebo | |---|---|---| | Nausea | 44.2% | 16.0% | | Diarrhea | 29.7% | 15.9% | | Vomiting | 24.5% | 6.3% | | Constipation | 24.2% | 11.1% | | Abdominal pain | 22.3% | 12.1% | | Dyspepsia | 9.0% | 5.9% | | Eructation | 8.9% | 1.5% | | Flatulence | 9.1% | 4.0% | | Gastroesophageal reflux | 8.6% | 3.4% |

Serious adverse events affected 9.8% of the semaglutide group versus 6.4% on placebo. Discontinuation due to adverse events occurred in 7.0% of semaglutide participants versus 3.8% on placebo [1].

STEP 2: Patients With Type 2 Diabetes

STEP 2 examined 1,210 adults with obesity and type 2 diabetes over 68 weeks [2]. This population showed a modestly lower gastrointestinal event rate compared to STEP 1, likely because metformin and other background therapies blunted GI sensitivity. Nausea incidence in the semaglutide 2.4 mg arm was 36.4% versus 14.1% for placebo. Hypoglycemia deserves specific mention here: serious hypoglycemia occurred in 0.5% of the semaglutide arm versus 1.6% on placebo in STEP 2 [2], a counterintuitive finding explained by improved glycemic control reducing the need for sulfonylureas.

STEP 3 and STEP 4: Behavioral Intervention and Withdrawal Data

STEP 3 (N=611) paired semaglutide 2.4 mg with intensive behavioral therapy. The GI adverse-event profile mirrored STEP 1, with nausea at 41.5% [3]. STEP 4 (N=803) is particularly instructive for long-term safety: participants who had already reached 2.4 mg were randomized to continue or switch to placebo. Adverse events were lower in the continuation arm during the withdrawal phase, confirming that peak GI burden occurs during dose escalation, not maintenance [4].

Gastrointestinal Side Effects: Mechanism, Timing, and Clinical Course

GLP-1 receptors are expressed throughout the gastrointestinal tract, and semaglutide's activation of those receptors slows gastric emptying, reduces appetite signaling, and increases satiety. These same mechanisms produce nausea, vomiting, and altered bowel habits.

Onset and Duration

The FDA-approved Wegovy prescribing information specifies a dose-escalation schedule that starts at 0.25 mg weekly and increases every four weeks to the 2.4 mg maintenance dose over 16 weeks [5]. This gradual ramp-up was designed specifically to reduce GI burden. Peak nausea reports cluster in weeks 4 through 12 based on adverse-event timing data from STEP 1. By week 20, the majority of affected patients report resolution or significant improvement.

Severity Distribution

Of all nausea events reported in STEP 1, 72.8% were rated mild or moderate. Severe nausea occurred in fewer than 5% of participants. Vomiting severe enough to require medical attention occurred in approximately 0.6% of the semaglutide arm [1]. The FDA prescribing label notes that GI events led to dose interruptions in a subset of patients, and clinicians may hold dose escalation at any step if tolerance is poor [5].

Managing GI Side Effects in Practice

Eating smaller portions, avoiding high-fat meals, and staying upright after eating reduce symptom burden in most patients. A 2023 review in JAMA Internal Medicine noted that dose-reduction strategies, rather than full discontinuation, salvage therapeutic response in the majority of GI-intolerant patients [6].

Gallbladder and Hepatic Adverse Events

Gallbladder disease emerges as a clinically meaningful safety signal with semaglutide 2.4 mg. In STEP 1, gallbladder-related adverse events occurred in 2.6% of the semaglutide arm versus 1.2% on placebo. Cholelithiasis (gallstones) accounted for most of these events [1].

Why GLP-1 Agonists Increase Gallstone Risk

Rapid weight loss of any cause increases bile cholesterol saturation and reduces gallbladder motility, both of which promote stone formation. GLP-1 receptor agonists may compound this by directly reducing gallbladder contractility. A 2022 meta-analysis in The Lancet covering 76 randomized trials and 103,371 participants found that GLP-1 receptor agonists as a class were associated with an odds ratio of 1.27 (95% CI 1.08 to 1.48) for gallbladder disease versus comparators [7].

Acute cholecystitis requiring hospitalization occurred in 0.6% of the semaglutide arm in STEP 1. Clinicians should counsel patients about biliary symptoms, particularly right upper quadrant pain after meals, before initiating Wegovy.

Cardiovascular Safety and the SELECT Trial

The SELECT cardiovascular outcomes trial (N=17,604) enrolled adults with established cardiovascular disease, overweight or obesity, and no diabetes. Published in the New England Journal of Medicine in 2023, SELECT showed semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) versus placebo over a mean follow-up of 34.2 months [8].

Adverse Events in SELECT

The SELECT adverse-event profile was consistent with STEP data. Serious adverse events occurred in 33.4% of the semaglutide arm versus 36.4% of placebo, a difference driven by the cardiovascular benefit itself rather than drug-related harms. GI adverse events occurred in 16.9% of semaglutide participants versus 7.6% on placebo [8]. The trial's size and duration make it the most strong long-term safety dataset for Wegovy to date.

Pancreatitis: Incidence and Current Evidence

Pancreatitis is listed as a warning in the Wegovy prescribing label. Across the pooled STEP 1 through STEP 4 trials, acute pancreatitis occurred in 0.2% of semaglutide participants versus 0.1% on placebo [5]. These numbers are low, but the condition carries serious morbidity, so FDA guidance specifies that Wegovy should be discontinued if pancreatitis is confirmed.

What the Evidence Actually Shows

A 2022 Cochrane review of GLP-1 receptor agonists found no statistically significant increase in pancreatitis risk across the drug class compared to active comparators or placebo (relative risk 1.11, 95% CI 0.74 to 1.65) [9]. The absolute numbers remain too small in individual trials to draw definitive conclusions. Clinicians should assess baseline pancreatic risk, including alcohol use and hypertriglyceridemia, before prescribing.

Heart Rate Effects

Semaglutide increases resting heart rate. In STEP 1, mean resting heart rate increased by 1.0 to 2.6 beats per minute from baseline in the semaglutide arm [1]. The SELECT trial confirmed a similar 1 to 3 bpm increase that persisted throughout the 34-month follow-up [8]. The clinical significance of this increase in patients without underlying arrhythmia is considered low by current prescribing guidelines, but patients with existing atrial fibrillation or tachyarrhythmia warrant closer monitoring.

Psychiatric and Neurological Adverse Events

Suicidal Ideation

In October 2023, the FDA added a section to the prescribing information for semaglutide products regarding suicidal ideation and behavior, following reports in the FDA Adverse Event Reporting System (FAERS) [10]. The STEP trials did not detect a statistically significant difference in suicidal ideation between semaglutide and placebo. However, because GLP-1 receptors are expressed in limbic brain regions, ongoing pharmacovigilance studies are evaluating this signal. The FDA's current guidance is to monitor patients with a history of depression or suicidal ideation and to discontinue if new symptoms emerge [5].

Headache and Fatigue

Headache occurred in 13.5% of the semaglutide arm versus 10.1% on placebo in STEP 1 [1]. Fatigue occurred in 10.7% versus 8.2% respectively. Both events were predominantly mild and resolved within the first 8 weeks of therapy.

Thyroid C-Cell Tumors: Black Box Warning

The Wegovy label carries an FDA black box warning for thyroid C-cell tumors based on rodent studies in which semaglutide caused dose-dependent increases in thyroid C-cell adenomas and carcinomas [5]. Human relevance remains undetermined. GLP-1 receptors are expressed on rodent thyroid C-cells but at much lower density in human thyroid tissue.

The FDA and the prescribing label both contraindicate Wegovy in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). No cases of medullary thyroid carcinoma attributable to semaglutide have been confirmed in human clinical trial data to date [5].

Injection Site Reactions

Local injection site reactions occurred in 5.1% of semaglutide participants versus 2.1% on placebo in STEP 1 [1]. These events were mild in the vast majority of cases, consisting of erythema, induration, or mild bruising. Rotating injection sites among the abdomen, thigh, and upper arm reduces local reaction frequency. No cases of severe injection site necrosis were reported in the STEP program.

Hypersensitivity and Rare Adverse Events

Serious allergic reactions, including anaphylaxis and angioedema, are listed as warnings in the prescribing label, though event rates in clinical trials were below 0.1% [5]. FAERS post-market data, queried through July 2024, shows case reports of alopecia, acute kidney injury (secondary to dehydration from GI losses), and non-arteritic anterior ischemic optic neuropathy (NAION), a rare vision-related event. A 2024 case-control study published in JAMA Ophthalmology found an adjusted odds ratio of 4.28 (95% CI 1.88 to 9.73) for NAION among semaglutide users with diabetes compared to non-users, though absolute rates remained very low and causality has not been established [11].

HealthRX Adverse Event Risk Stratification Framework

The table below integrates incidence data from STEP 1 through STEP 4, SELECT, FDA labeling, and FAERS to classify Wegovy adverse events by frequency and clinical priority. This framework is original to HealthRX and is intended for use during patient counseling prior to initiating therapy.

| Risk Tier | Adverse Event | Incidence (Semaglutide) | Incidence (Placebo) | Action | |---|---|---|---|---| | Very Common (>10%) | Nausea, diarrhea, vomiting, constipation | 24 to 44% | 6 to 16% | Counsel proactively; manage with dietary changes | | Common (1 to 10%) | Gallbladder disease, headache, fatigue, injection site reaction | 2 to 14% | 1 to 10% | Monitor; assess biliary symptoms at follow-up | | Uncommon (0.1 to 1%) | Pancreatitis, hypoglycemia (diabetes subgroup), severe hypersensitivity | 0.1 to 0.5% | 0.1 to 1.6% | Discontinue if confirmed; evaluate risk pre-prescribing | | Rare (<0.1%) | Anaphylaxis, medullary thyroid carcinoma, NAION | <0.1% | <0.1% | Contraindicate in high-risk patients; report to FAERS | | Signal Under Evaluation | Suicidal ideation, alopecia, acute kidney injury | Post-market FAERS data | Unclear | Screen psychiatric history; monitor hydration |

This tiered approach aligns with the ICH E1 guideline frequency convention used in EU SmPC labeling and mirrors the structure recommended by the FDA's Guidance for Industry on Clinical Safety Data Management [12].

Rates of Discontinuation Across Trials

Understanding why patients stop Wegovy matters clinically. Discontinuation due to adverse events across the STEP trials averaged 7 to 9% in semaglutide arms versus 3 to 4% in placebo arms. GI adverse events drove 59% of discontinuations in the semaglutide arms of STEP 1 through STEP 3 [1, 2, 3]. The SELECT trial reported a slightly lower discontinuation rate of 16.6% for any reason in the semaglutide arm over 34 months versus 15.2% on placebo, suggesting long-term tolerability improves once dose stabilization is achieved [8].

Clinicians at HealthRX note that slower dose titration, holding at 1.7 mg rather than advancing to 2.4 mg, reduces GI discontinuations without meaningfully compromising weight-loss efficacy in patients with low GI tolerance. The prescribing label explicitly permits this strategy [5].

What FAERS Data Adds to Trial Evidence

FDA Adverse Event Reporting System data extends the safety picture beyond controlled trial conditions. As of Q1 2025, semaglutide injectable products (all doses, all indications combined) had accumulated more than 40,000 FAERS reports since Ozempic's 2017 approval [10]. Disproportionality analyses using reporting odds ratios have identified the following signals not fully captured by controlled trials: gastroparesis (delayed gastric emptying with prolonged nausea and vomiting), intestinal obstruction, and hair thinning.

The American Gastroenterological Association published a clinical practice update in 2023 recommending that providers hold GLP-1 receptor agonists 7 days before elective procedures requiring general anesthesia, due to aspiration risk from delayed gastric emptying, even in patients without overt gastroparesis symptoms [13]. This guidance directly addresses a real-world safety concern that the STEP trials were not designed to detect.